Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Zweiker, D; Koppelstätter, C; Hohenstein, K; Lang, I; Perl, S; Bugger, H; Brandt, MC; Horn, S; Binder, RK; Watschinger, B; Frick, M; Niessner, A; Weber, T.
Renal sympathetic denervation 2024 in Austria: recommendations from the Austrian Society of Hypertension : Endorsed by the Austrian Society of Nephrology and the Working Group of Interventional Cardiology of the Austrian Society of Cardiology.
Wien Klin Wochenschr. 2024; 136(Suppl 14):559-569
Doi: 10.1007/s00508-024-02440-3
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
-
Zweiker David
- Co-Autor*innen der Med Uni Graz
-
Bugger Heiko Matthias
-
Perl Sabine
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Renal sympathetic denervation (RDN) is an interventional supplement to medical treatment in patients with arterial hypertension. While the first sham-controlled trial, SYMPLICITY HTN‑3 was neutral, with improved procedural details, patient selection and follow-up, recent randomized sham-controlled trials of second-generation devices show a consistent blood pressure lowering effect of RDN, as compared to sham controls. These new data and the recent U.S. Food and Drug Administration (FDA) premarket approval of two RDN devices are the basis for the present recommendations update.This joint position paper from the Austrian Society of Hypertension, together with the Austrian Society of Nephrology and the Working Group of Interventional Cardiology from the Austrian Society of Cardiology includes an overview about the available evidence on RDN and gives specific recommendations for the work-up, patient selection, pretreatment, procedural management and follow-up in patients undergoing RDN in Austria. Specifically, RDN may be used in clinical routine care, together with lifestyle measures and antihypertensive drugs, in patients with resistant hypertension (i.e. uncontrolled blood pressure on 3 antihypertensive drugs) and in those with uncontrolled hypertension, after adequate work-up, if institutional, patient-related and procedural conditions are fulfilled.
- Find related publications in this database (using NLM MeSH Indexing)
-
Humans - administration & dosage
-
Sympathectomy - methods, standards
-
Hypertension - surgery, therapy
-
Austria - administration & dosage
-
Cardiology - standards
-
Kidney - innervation
-
Nephrology - standards
-
Practice Guidelines as Topic - administration & dosage
-
Antihypertensive Agents - therapeutic use
-
Treatment Outcome - administration & dosage
- Find related publications in this database (Keywords)
-
Resistant hypertension
-
Uncontrolled hypertension
-
Arterial hypertension
-
Interventional therapy
-
Consensus report